在状细胞疾病管理中,thalidomide和hydroxyurea的协同潜力:一个有前途的组合疗法
Priyanka Samal1, Asutosh Samal2, Debananda Lenka1
1Department of Clinical Hematology, Institute of Medical Sciences & Sum Hospital, Siksha 'O' Anusandhan Deemed to Be University, Bhubaneswar, 751003 Odisha India.
氧尿素和thalidomide通过增加胎儿血红蛋白 (HbF) 有效地管理状细胞疾病和β-thalassemia. 这些药物为血红蛋白病变提供了改善的治疗结果.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 遗传学 遗传学 是一个
背景情况:
- 状细胞疾病 (SCD) 和β-thalassemia是严重的遗传性血液疾病,导致贫血和并发症.
- 目前的治疗方法旨在控制症状并改善生活质量.
研究的目的:
- 审查氨酸urea和thalidomide的分子机制和临床益处.
- 突出其在优化SCD和β-thalassemia治疗策略方面的潜力.
主要方法:
- 关于基尿素和thalidomide在血红蛋白病变中的现有文献的综述.
- 分析它们对胎儿血红蛋白 (HbF) 生产和疾病标志物的影响.
主要成果:
- 基尿素增加HbF,减少HbS聚合,并减轻SCD/β-thalassemia并发症.
- thalidomide通过调节马环球蛋白基因诱导HbF,并具有抗炎作用.
- 结合疗法显示出增强临床益处的前景.
结论:
- 氧尿素是SCD的基石疗法.
- thalidomide是β-thalassemia的有前途的药物,并可能作为辅助疗法.
- 这两种药物都为优化血红蛋白病症管理提供了显著的潜力.
更多相关视频
08:23Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry
Published on: November 5, 2019
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
相关概念视频
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Multiple Allele Traits
Antihypertensive Drugs: Thiazide-Class Diuretics
Heart Failure V: Medical Management
Therapeutic Drug Monitoring: Affecting Factors
